This session will focus on the use of genetic tools to identify novel targets for therapy and the discovery of biomarkers that can be used to predict responses to therapy in the clinic.
Symposium: Cancer Genomics and Drug Discovery

Functional genomics to identify and validate cancer targets; William C. Hahn. Dana-Farber Cancer Inst., Boston, MA

Gene expression-based approaches to small molecule discovery for cancer; Kimberly Stegmaier. Dana-Farber Cancer Inst., Boston, MA

Towards functional annotation of the cancer genome; Michael A. White. University of Texas Southwestern Medical Center, Dallas, TX

Finding mechanisms of drug resistance using functional genetic screens; René Bernards. The Netherlands Cancer Institute, Amsterdam, Netherlands,